- Clinical Trials
- April 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Report
- October 2024
- 196 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2025
- 189 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- January 2025
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- August 2024
- 170 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- May 2024
- 130 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- July 2024
- 88 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- December 2020
- 100 Pages
Asia Pacific
From €2139EUR$2,250USD£1,797GBP
- Report
- June 2023
- 110 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4706EUR$4,950USD£3,953GBP
- Report
- July 2022
- 60 Pages
China
From €2804EUR$2,950USD£2,356GBP
- Report
- July 2022
- 30 Pages
Global
From €1141EUR$1,200USD£958GBP
- Report
- February 2024
- 113 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- October 2023
- 172 Pages
South Korea
From €3421EUR$3,599USD£2,874GBP
Presbyopia Drug market is a segment of the Optical Disorders Drugs market that focuses on the treatment of presbyopia, a condition that affects the ability of the eye to focus on near objects. Presbyopia is a natural part of aging, and is caused by the gradual loss of elasticity in the lens of the eye. Presbyopia drugs are used to improve near vision and reduce the need for reading glasses. These drugs are typically administered as eye drops, and can be used to treat both presbyopia and other refractive errors.
The Presbyopia Drug market is highly competitive, with a number of companies offering products to treat the condition. Companies in the market include Allergan, Bausch + Lomb, Novartis, Santen, and Shire. Show Less Read more
